Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01203787 · ClinicalTrials.gov registry record · Phase 4
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
A Phase 4 study of Hepatocellular Carcinoma, sponsored by University of Florida.
- Completed
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
- 9
- Study locations
NCT01203787: Completed Phase 4 study of Hepatocellular Carcinoma, sponsored by University of Florida.
NCT01203787 is a Phase 4 study of Hepatocellular Carcinoma that has completed, run by University of Florida. The registered enrollment target is 120 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (53% lower). The trial reports 9 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01203787, a Phase 4 study of Hepatocellular Carcinoma, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
- 9
- Study locations
Study Summary
Open-label study to evaluate the safety and tolerability of Sorafenib dose ramp-up (starting at a lower dose and then gradually increasing the dose) versus standard Sorafenib dosing in subjects with unresectable and/or metastatic hepatocellular carcinoma.
Primary Outcome
This outcome measure table shows the median cumulative dose delivered to the subjects randomized to the standard dosing regimen (N=63) and ramp-up regimen (N=57) at 4 months of treatment.
Conditions Studied
Interventions
- DRUG Sorafenib Standard Dosing Regimen
- DRUG Sorafenib Ramp-Up Regimen
Study Locations (9)
Florida
- University of Florida Hepatology - Gainesville
- Mayo Clinic - Jacksonville
- Florida Hospital Transplant Center - Orlando
- Tampa General Hospital - Tampa
Texas
- University of Texas Health Science Center Houston - Houston
- Brooke Army Medical Center - San Antonio
Illinois
- Loyola University Medical Center - Maywood
Michigan
- Henry Ford Health System - Detroit
Pennsylvania
- Drexel University College of Medicine - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2010-12 |
| Est. Completion | 2014-03 |
| Phase | Phase 4 |
What the finished NCT01203787 record still lists
NCT01203787 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Sorafenib Standard Dosing Regimen is the first listed.
NCT01203787 lists 9 locations in 5 states (Florida, Texas, Illinois).
Frequently Asked Questions
What is clinical trial NCT01203787 about?
NCT01203787 is a clinical study titled "Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)". Open-label study to evaluate the safety and tolerability of Sorafenib dose ramp-up (starting at a lower dose and then gradually increasing the dose) versus standard Sorafenib dosing in subjects with unresectable and/or metastatic hepatocellular carcinoma.
What is the current status of trial NCT01203787?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2010-12. Estimated completion is 2014-03.
What conditions does trial NCT01203787 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT01203787?
The interventions under investigation include: Sorafenib Standard Dosing Regimen (DRUG), Sorafenib Ramp-Up Regimen (DRUG).
Who is sponsoring clinical trial NCT01203787?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01203787 being conducted?
This trial has 9 study locations across Florida, Illinois, Michigan, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01203787's enrollment target sits among peer trials
120 52nd of 145 higher than 93 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
RECRUITING · Phase 4
-
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
RECRUITING · Phase 4
-
Molecular Basis of Pediatric Liver Cancer
RECRUITING
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia